Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August: William Blair Biotech Focus Conference 2020 Date: Thursday,
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (NASDAQ:RTRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.55) by 60 percent. This is a 62.07 percent increase over losses of $(0.58) per share from the same
Benzinga · 07/30 20:13
Retrophin Reports Second Quarter 2020 Financial Results
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equi
GlobeNewswire · 07/30 20:01
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Retrophin EPS beats by $0.14, beats on revenue
Seeking Alpha · 07/30 04:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.